Eli Lilly has said it is prepared ... the dual GIP/GLP-1 receptor agonist in the company's Mounjaro drug for type 2 diabetes and obesity. The SURMOUNT-REAL UK study will be carried out in ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy ... of the disease to do what matters most to them." The company stopped short of commenting directly on NICE's draft ...

It’s been a rough month for several clinical amyotrophic lateral sclerosis (ALS) candidates, but that’s not stopping Eli Lilly from pursuing ... slower decline, the company said in the release.

Eli Lilly’s recently-announced investment into the UK’s life sciences sector “marks a pivotal moment for the industry”, according to GlobalData’s senior analyst in business fundamentals ...